NYU Langone Health: Pancreatic Neoplasms trials

The registry lists 10 Pancreatic Neoplasms studies with NYU Langone Health as lead sponsor. 1 are open to participants now and 3 have results posted.

Phase 1 5Phase 2 4No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)RecruitingNCT05723107Phase 1
• Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic CancerTerminatedNCT03599362Phase 2Results posted
• Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic CancerCompletedNCT00696696Phase 2Results posted
• Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic CancerTerminatedNCT00463840Phase 1/2Results posted
• Clinician Decision Making Regarding Surveillance for Low-risk Intraductal Papillary Mucinous Neoplasms of The PancreasCompletedNCT06311032
• A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic CancerActive, not recruitingNCT05984602Phase 1
• Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic CancerCompletedNCT05483075Not applicable
• Oral Microbiome and Pancreatic CancerCompletedNCT03302637
• Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic CancerWithdrawnNCT02868632Phase 1
• Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic CancerCompletedNCT00003332Phase 1/2